but-2-yne-1,4-diol : A butynediol that is but-2-yne substituted by hydroxy groups at positions 1 and 4. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 8066 |
| CHEMBL ID | 3187551 |
| CHEBI ID | 16413 |
| MeSH ID | M0054685 |
| Synonym |
|---|
| CHEBI:16413 , |
| 1,4-dimethoxyacetylene |
| brn 1071237 |
| nsc 834 |
| un2716 |
| 1,4-butinodiol [spanish] |
| 2-butin-1,4-diol [czechoslovakia] |
| butynediol-1,4 [french] |
| einecs 203-788-6 |
| hsdb 2004 |
| ai3-61467 |
| agrisynth b3d |
| 1,4-butynediol (van) |
| 2-butin-1,4-diol [czech] |
| inchi=1/c4h6o2/c5-3-1-2-4-6/h5-6h,3-4h |
| 2-butyne-1,4-diol |
| but-2-yne-1,4-diol |
| C02497 |
| 1,4-butynediol |
| nsc834 |
| nsc-834 |
| 2-butynediol |
| wln: q2uu2q |
| 110-65-6 |
| 1,4-dihydroxy-2-butyne |
| bis(hydroxymethyl)acetylene |
| 2-butyne-1,4-diol, 99% |
| B0749 |
| 1,2-dihydroxydimethylacetylene |
| AKOS000118736 |
| FT-0664174 |
| NCGC00249014-01 |
| dtxsid4021921 , |
| cas-110-65-6 |
| NCGC00256535-01 |
| tox21_302875 |
| dtxcid901921 |
| NCGC00258836-01 |
| tox21_201284 |
| 1,4-butynediol [un2716] [poison] |
| 2-butin-1,4-diol |
| butynediol-1,4 |
| unii-axh202fpqm |
| ec 203-788-6 |
| 1,4-butinodiol |
| 4-01-00-02687 (beilstein handbook reference) |
| axh202fpqm , |
| FT-0611639 |
| 1,4-butynediol [hsdb] |
| un 2716 |
| 1,2-dimethoxyacetylene |
| 2-butyn-1,4-diol |
| 1,4dihydroxy-2-butyne |
| but-2-yne-1,4diol |
| 2-butyne-l,4-diol |
| 2-butyne-1,4-di-ol |
| CHEMBL3187551 |
| J-002458 |
| F0001-0223 |
| mfcd00002915 |
| Q209328 |
| EN300-19323 |
| STL185542 |
| E78871 |
| butynediol 1,4-butynediol 2-butyne-1,4-diol |
| 1,4-butyne glycol |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The oral LD50 values for BYD were 132 mg kg-1 in male rats and 176 mg kg-1 in female rats." | ( Acute toxicity of 2-butyne-1,4-diol in laboratory animals. Czajkowska, T; Jedrychowski, RA; Stetkiewicz, I; Stetkiewicz, J, 1992) | 0.62 |
| Class | Description |
|---|---|
| butynediol | Any acetylenic compound that is butyne substituted by two hydroxy groups at unspecified positions. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| acetylcholinesterase | Homo sapiens (human) | Potency | 50.9887 | 0.0025 | 41.7960 | 15,848.9004 | AID1347398 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 63.1503 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 78.0558 | 0.0006 | 57.9133 | 22,387.1992 | AID1259377 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 55.2593 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 22.1886 | 0.1434 | 27.6121 | 59.8106 | AID1159516 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 45.4877 | 0.0578 | 21.1097 | 61.2679 | AID1159526; AID1159528 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 126.7930 | 0.0391 | 47.5451 | 146.8240 | AID1224845 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 27.3060 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 54.9477 | 0.0420 | 27.3789 | 61.6448 | AID743210 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 68.5896 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (33.33) | 18.7374 |
| 1990's | 3 (25.00) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (34.84) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (7.69%) | 6.00% |
| Case Studies | 2 (15.38%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (76.92%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||